Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hangzhou Alltest Biotech CoSHSE:688606 +1.04%53 EBITDA Margin % is 11.24% as of Mar. 2026, which is 69% below its 10-year median of 36.34. GuruFocus rates SHSE:688606 with a GF Score™ of 53/100 and a GF Value™ of ¥85.89 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Hangzhou Alltest Biotech Co ranks better than 81.47% on this metric.
Hangzhou Alltest Biotech Co (SHSE:688606) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hangzhou Alltest Biotech Co EBITDA Margin % Related Terms
Hangzhou Alltest Biotech Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688606 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Hangzhou Alltest Biotech Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Alltest Biotech Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hangzhou Alltest Biotech Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Hangzhou Alltest Biotech Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Alltest Biotech Co (SHSE:688606) has a EBITDA Margin % of 11.24% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hangzhou Alltest Biotech Co and its competitors. This is 69% below median its historical median of 36.34. Over the past decade, Hangzhou Alltest Biotech Co's EBITDA Margin % has ranged from 21.97 to 71.98. According to the industry distribution chart, Hangzhou Alltest Biotech Co ranks #151 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 18.5%.
Is Hangzhou Alltest Biotech Co's EBITDA Margin % too high?
Hangzhou Alltest Biotech Co's current EBITDA Margin % of 11.24% is 69% below median its 10-year median of 36.34. Over the past 10 years, this metric has ranged from a low of 21.97 to a high of 71.98. The Medical Devices & Instruments industry median EBITDA Margin % is 7.52. Hangzhou Alltest Biotech Co's value of 11.24% is 49.5% above this industry median. Based on the distribution chart, Hangzhou Alltest Biotech Co ranks #151 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Hangzhou Alltest Biotech Co has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Alltest Biotech Co's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Hangzhou Alltest Biotech Co ranks #151 out of 815 companies for EBITDA Margin %. This places Hangzhou Alltest Biotech Co in the top 19% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.52. Hangzhou Alltest Biotech Co's value of 11.24% is 49.5% above this benchmark. Historically, Hangzhou Alltest Biotech Co's own EBITDA Margin % has ranged from 21.97 to 71.98 over the past decade. While the company's 10-year median is 36.34 vs. the industry median of 7.52, Hangzhou Alltest Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.52, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou Alltest Biotech Co's current EBITDA Margin % of 11.24% is 49.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hangzhou Alltest Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Alltest Biotech Co's current EBITDA Margin % is 11.24%, which is 69% below median its own 10-year median of 36.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Alltest Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Alltest Biotech Co (SHSE:688606) is currently considered Possible Value Trap. The stock's GF Value™ is ¥85.89, compared to a current price of ¥43.92 — trading 48.9% below its estimated fair value. The current EBITDA Margin % is 11.24%, which is 69% below median its 10-year median of 36.34 and 49.5% above the Medical Devices & Instruments industry median of 7.52. Hangzhou Alltest Biotech Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hangzhou Alltest Biotech Co (SHSE:688606), the current EBITDA Margin % is 11.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou Alltest Biotech Co (SHSE:688606) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou Alltest Biotech Co stock appears to be undervalued.
The current stock price of ¥43.92 is trading 48.9% below its estimated GF Value™ of ¥85.89.
GuruFocus considers Hangzhou Alltest Biotech Co to be Possible Value Trap.
Key valuation signals for SHSE:688606:
EBITDA Margin %: 11.24% (69% below median its 10-year median of 36.34)
GF Value™: ¥85.89 vs. price of ¥43.92 (48.9% below fair value)
Industry Position: 49.5% above the Medical Devices & Instruments median (#151 of 815)
No single metric tells the full story. See the SHSE:688606 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688606 has been successfully added to your 
